Updated: Apr 22, 2009
Ankle dislocations occur when significant force applied to the joint results in loss of opposition of the articular surfaces. Because of the large amount of force required and the inherent stability of the joint, dislocation of the ankle joint is rarely seen without an associated fracture.
The ankle joint is designed for a balance of stability and flexibility, particularly the former. Joint stability is provided by close articulation of the talus with the tibia and fibula. The mortise design further enhances the stability of the configuration.
The talus is trapezoidal in shape, with the greater width anteriorly. As the joint moves into plantar flexion, the talus becomes narrower, resulting in a decrease in stability. During normal walking, the ankle joint bears 3-5 times the body weight. This factor increases several fold during running and jumping activities. As weight is applied on heel strike, the fibula descends to increase stability of the ankle joint.
Children and adolescents have the most ankle dislocations.
A detailed history regarding the mechanism of injury often helps predict the type of injuries to expect. Furthermore, an understanding of the injury mechanism aids treatment, since an opposite force is required in reduction of the joint. Four types of dislocations are seen around the ankle joint.
Ankle Injury, Soft Tissue
Dislocations, Foot
Fractures, Ankle
Fractures, Foot
In cases of superior ankle dislocations, concomitant spine injury and fracture of the calcaneus should be sought.
Dislocations of the ankle are, by definition, unstable due to accompanying disruption of the lateral or medial ligaments or the tibiofibular syndesmosis. These require an immediate orthopedic consultation for internal fixation of any associated fractures and repair of capsular or ligamentous tears.
Drugs used to treat the pain associated with dislocations include analgesics and anxiolytics.
Pain control is essential for quality patient care. It ensures patient comfort, promotes pulmonary toilet, and aids physical therapy regimens. Many analgesics have sedating properties that benefit patients who have sustained injuries.
Narcotic analgesic with greater potency and much shorter half-life than morphine sulfate. DOC for conscious sedation analgesia. With short duration (30-60 min) and ease of titration, an excellent choice for pain management and sedation. Easily and quickly reversed by naloxone. After initial dose, subsequent doses should not be titrated more frequently than q3h or q6h.
0.5-1 mcg/kg/dose IV/IM q30-60min
<2 years: 2-3 mcg/kg/dose IV/IM q30-60min
2-12 years: 1-2 mcg/kg/dose IV/IM q60min
>12 years: Administer as in adults
Phenothiazines may antagonize analgesic effects; tricyclic antidepressants may potentiate adverse effects
Documented hypersensitivity; hypotension; potentially compromised airway in which establishing rapid airway control would be difficult
C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
Caution in hypotension, respiratory depression, constipation, nausea, emesis, and urinary retention; idiosyncratic reaction, known as chest wall rigidity syndrome, may require neuromuscular blockade to increase ventilation
Drug combination indicated for relief of moderately severe to severe pain. DOC for aspirin-hypersensitive patients. Different strengths available.
1-2 tab or cap PO q4-6h prn
0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose oxycodone
Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants may increase toxicity
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
Duration of action may increase in elderly patients; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4,000 mg/24 h of acetaminophen; higher doses may cause liver toxicity
Drug combination indicated for relief of moderately severe to severe pain.
1-2 tab or cap PO q4-6h prn
0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose oxycodone
Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants may increase toxicity; may potentiate anticoagulant effects of warfarin
Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma; because of association of aspirin with Reye syndrome, do not use in children (<16 y) who have the flu
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Duration of action may increase in elderly patients; caution in renal or liver impairment, peptic ulcer disease, and erosive gastritis
Drug combination indicated for treatment of mild to moderately severe pain.
30-60 mg/dose based on codeine content PO q4-6h or 1-2 tab q4h; not to exceed 12 tab/d
0.5-1 mg/kg/dose based on codeine content PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen
CNS depressants or tricyclic antidepressants may increase toxicity
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
Caution in patients dependent on opiates because this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction
DOC for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Various IV doses are used; commonly titrated until desired effect obtained.
Starting dose: 0.1 mg/kg IV/IM/SC
Maintenance dose: 5-20 mg/70 kg IV/IM/SC q4h
Relatively hypovolemic patients: Start with 2 mg IV/IM/SC; reassess hemodynamic effects of dose
Infants and children: 0.1-0.2 mg/kg dose IV/IM/SC q2-4h prn; not to exceed 15 mg/dose; may initiate at 0.05 mg/kg/dose
Phenothiazines may antagonize analgesic effects of opiate agonists; tricyclic antidepressants, MAO inhibitors, and other CNS depressants may potentiate adverse effects of morphine
Documented hypersensitivity; hypotension; potentially compromised airway where establishing rapid airway control would be difficult
C - Fetal risk revealed in studies in animals but not established or not studies in humans; may use if benefits outweigh risk to fetus
Caution in hypotension, respiratory depression, nausea, emesis, constipation, urinary retention, atrial flutter, and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate
Patients with painful injuries usually experience significant anxiety. Anxiolytics allow the clinician to administer a smaller analgesic dose to achieve the same effect.
Depresses all levels of CNS, including limbic and reticular formation, possibly by increasing activity of GABA, a major inhibitory neurotransmitter. Individualize dosage and increase cautiously to avoid adverse effects.
5-10 mg PO/IV/IM q3-4h; repeat q2-4h prn; not to exceed 30 mg in 8-h period
0.05-0.3 mg/kg/dose IV/IM over 2-3 min; repeat in 2-4 h prn; 0.12-0.8 mg/kg/d PO divided q6-8h; not to exceed 10 mg/dose
Phenothiazines, barbiturates, alcohols, or MAOIs may increase CNS toxicity
Documented hypersensitivity; narrow-angle glaucoma
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Caution with other CNS depressants, low albumin levels, or hepatic disease (may increase toxicity)
Sedative hypnotic in benzodiazepine class that has short onset of effect and relatively long half-life. By increasing GABA, a major inhibitory neurotransmitter, may depress all levels of CNS, including limbic and reticular formation. When patient needs to be sedated for >1 d this medication is excellent. Monitor patient's blood pressure after administering dose and adjust as necessary.
1-10 mg/d IV divided bid/tid; not to exceed 4 mg/dose
0.05-0.1 mg/kg IV slowly over 2-5 min; may repeat a dose of 0.05 mg/kg IV slowly
Alcohol, phenothiazines, barbiturates, or MAOIs may increase CNS toxicity
Documented hypersensitivity; preexisting CNS depression; hypotension; narrow-angle glaucoma
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Caution in renal or hepatic impairment, myasthenia gravis, organic brain syndrome, or Parkinson disease
Complications of ankle dislocation may include the following:
Daffner RH. Ankle trauma. Semin Roentgenol. Apr 1994;29(2):134-51. [Medline].
Daffner RH. Ankle trauma. Radiol Clin North Am. Mar 1990;28(2):395-421. [Medline].
Distefano S, Divita G. A case of pure dislocation of the ankle joint. Ital J Orthop Traumatol. Mar 1988;14(1):133-7. [Medline].
Finkemeier C, Engebretsen L, Gannon J. Tibial-talar dislocation without fracture: treatment principles and outcome. Knee Surg Sports Traumatol Arthrosc. 1995;3(1):47-9. [Medline].
Graeme KA, Jackimczyk KC. The extremities and spine. Emerg Med Clin North Am. May 1997;15(2):365-79. [Medline].
Greenbaum MA, Pupp GR. Ankle dislocation without fracture: an unusual case report. J Foot Surg. May-Jun 1992;31(3):238-40. [Medline].
Griffiths HJ. Trauma to the ankle and foot. Crit Rev Diagn Imaging. 1986;26(1):45-105. [Medline].
Krishnamurthy S, Schultz RJ. Pure posteromedial dislocation of the ankle joint. A case report. Clin Orthop Relat Res. Dec 1985;(201):68-70. [Medline].
Merianos P, Papagiannakos K, Hatzis A, Tsafantakis E. Peritalar dislocation: a follow-up report of 21 cases. Injury. Nov 1988;19(6):439-42. [Medline].
Moehring HD, Tan RT, Marder RA, Lian G. Ankle dislocation. J Orthop Trauma. 1994;8(2):167-72. [Medline].
Mooney JF, Naylor PT, Poehling GG. Anterolateral ankle dislocation without fracture. South Med J. Feb 1991;84(2):244-7. [Medline].
Schuberth JM. Diagnosis of ankle injuries: the essentials. J Foot Ankle Surg. Mar-Apr 1994;33(2):214. [Medline].
Wilson AB, Toriello EA. Lateral rotatory dislocation of the ankle without fracture. J Orthop Trauma. 1991;5(1):93-5. [Medline].
Wroble RR, Nepola JV, Malvitz TA. Ankle dislocation without fracture. Foot Ankle. Oct 1988;9(2):64-74. [Medline].
ankle dislocation, ankle joint, dislocated ankle, ankle injuries, ankle fracture, ankle sprain, sprained ankle, broken ankle, tibia, fibula, talus, ankle bones, posterior ankle dislocation, anterior ankle dislocation, superior ankle dislocation, lateral ankle dislocation, dislocation of the ankle, dislocation of the ankle joint
James E Keany, MD, FACEP, Medical Director, JetWest International Air Ambulance; Consulting Staff, Department of Emergency Services, Mission Hospital Regional Medical Center; Host of Healthbuzz at Jim.MD
James E Keany, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American College of Sports Medicine, and California Medical Association
Disclosure: Nothing to disclose.
Joseph J Sachter, MD, FACEP, Consulting Staff, Department of Emergency Medicine, Muhlenberg Regional Medical Center
Joseph J Sachter, MD, FACEP is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Physician Executives, American Medical Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.
David B Levy, DO, FACEP, FAAEM, Chairman, Department of Emergency Medicine, St Elizabeth Health Center; Associate Professor of Emergency Medicine, Northeastern Ohio Universities College of Medicine
David B Levy, DO, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American Medical Informatics Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)